News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Top Trends, Takeaways from DIA

July 9, 2019
By Lisa Henderson
Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-07-01-2019
Volume 39
Issue 7

Highlighting the biggest observations from this year's DIA Annual Meeting-topics likely to continue to dominate industry headlines for the foreseeable future.

The DIA Annual Meeting held in late June offered its signature high-quality educational sessions that address numerous topics, with much global regulatory authority presence. The exhibit floor, however, showcased more often than not, services and technology applications for clinical trials and operations, many of which focus on patient centricity. Clearly, as we addressed in-depth in Pharm Exec’s March issue, patient centricity is not just a

Lisa Henderson

way to get patients recruited more quickly into trials; it is a more holistic approach that spans a pharmaceutical company’s overall approach or philosophy to its mission. 

At DIA, Parexel held a private roundtable and unveiled research that shows when a company employs patient centricity in its drug development designs, the likelihood of launch increases 19%. Suffice to say, there will be more news coming out around that report. However, other trends or observations heard around DIA comprise the remainder of this column.

Change management. Culture may eat strategy for lunch but change management within an organization hoping to improve and innovate processes through improved technologies is a reality. From implementing patient-centric processes throughout an organization, to the ever-present frustration around implementing risk-based or targeted monitoring, it seems getting people to let go of the old and bring in the new is the norm. Even a reference to companies that still use paper-based data collection will get a chuckle in a room, but, be sure, it is still a widespread practice. 

Crossover technologies. I heard from many newer companies coming from the healthcare side, hoping to implement what they do here on the pharma side. Mostly in regard to patient-facing or person-facing technologies, uses include telemedicine platforms, training, home health, and apps. Even technologies used in postmarket drug approval, such as registries for longer-term outcomes data, are seeing the opportunities to apply their knowledge upstream to the research area.

Personalized medicine and powering smaller population trials is here. While the general notion is that this direction is relegated to the rare and orphan disease space and is a longer way in the future, practice says it’s here. And while the rare space has more experience with it, there are larger oncology organizations utilizing adaptive trial designs that address sub-types, to apply the person with the phenotypes best-suited for success. Patients seeking trials will smartly be looking for the ones that present maybe only a fewer percentage points better for their specific mutation, but 5% to 10% differences will matter to the trial in which they commit.

Continued frustration with CROs. As a whole, CROs run the gamut of services, sizes, and provider models, but no matter how a provider may want to change what category they are labeled, CROs are what they are stuck under. And, as a whole, one bad experience with a CRO can leave a pharma company swearing off of all types of CROs forever. One bad apple spoils the bunch, so to speak. 

We have reported before in our pages on the less-than-ideal experiences that emerging biopharma is experiencing with their CROs. From inattention to detail, to performing (and charging) for unnecessary patient tests, to execution failures in dealing with smaller patient populations with rare diseases. Emerging biopharma has a range of needs with limited resources, and in some cases, limited knowledge on where to start. CROs need to start upping their relationship game and communication skills to get into the weeds with emerging biopharma on what is truly needed in whatever capacity-trial to commercialization-to get to some core understandings.

Data. It can’t be stressed enough that the only way forward is through data. Even those that collect information and conduct processes on paper, while getting a laugh, are setting themselves up for longer-term pain. Large pharma can afford to buy data sets, to acquire assets to improve, manage, and integrate data toward improvements on all levels of uses for predictive analytics, risk-based approaches to everything, and eventually artificial intelligence to model and simulate scenarios. Smaller companies are left with choosing the best service providers to help them with those needs. Data collection, cleanliness and handling for trials, submissions, and all else requires data experts and data scientists. Look for more organizations to push data scientists closer to all needs for pharma companies. Learn to be data smart. 

By the end of this month, the Pharm Exec team will have completed our content calendar for 2020, determining the month-by-month editorial topics for the specific issues. This doesn’t include the majority of our information that is posted online, which also focuses on these and many more trends and observations. But these topics will continue to dominate the headlines for the remainder of this year, and into the next.

 

Lisa Henderson is Editor-in-Chief of Pharm Exec. She can be reached at lhenderson@mmhgroup.com. Follow Lisa on Twitter: @trialsonline

Download Issue PDF
Articles in this issue

Creating an ‘Unbossed’ Environment in the Workplace
Creating an ‘Unbossed’ Environment in the Workplace
Dean Erhardt.jpg
Proposed Rebates Rule Raises Tough Questions
Formularies PQ2.png
Drug Formulary Decisions: Fixing a Broken System
Open label PQ.png
The Feasibility of Patient Insights Before Launch
Compliance Disruptors
Compliance Disruptors
Asia’s Complex Compliance Landscape
Asia’s Complex Compliance Landscape
Compliance as Usual Doesn’t Cut it Anymore
Compliance as Usual Doesn’t Cut it Anymore
European Pricing Talks: A lot of Smoke—or is it Fire?
FDA Maps Pathway to More Accessible Biosimilars
FDA Maps Pathway to More Accessible Biosimilars
Lisa Henderson thumbnail.jpg
Top Trends, Takeaways from DIA
Pharma & Biotech: Financial Pulse-Check, Outlook
Pricing in DTC: Adjusting to the New World
Pharmaceutical Executive, July 2019 Issue (PDF)
Country Report: Egypt
Recent Videos
Related Content

Stock.adobe.com

GSK and Lifetime Produce Meningitis-Themed Film

Mike Hollan
May 21st 2025
Article

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children are vaccinated against all strains.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Andres Acosta, MD, PhD

Predicting GLP-1 Side Effects: Q&A with Andres Acosta, MD, PhD

Mike Hollan
May 20th 2025
Article

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision medicine.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

Related Content

Stock.adobe.com

GSK and Lifetime Produce Meningitis-Themed Film

Mike Hollan
May 21st 2025
Article

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children are vaccinated against all strains.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Andres Acosta, MD, PhD

Predicting GLP-1 Side Effects: Q&A with Andres Acosta, MD, PhD

Mike Hollan
May 20th 2025
Article

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision medicine.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.